Promising New Gene Therapy for a Genetic Form of Parkinson’s

Spur Therapeutics has shared encouraging preclinical results for SPR301, a potential gene therapy for people living with a genetic form of Parkinson’s disease linked to GBA1 mutations. These findings were presented at the 2nd Annual GBA1 Meeting, hosted by McGill University and supported by several major Parkinson’s research foundations. 🔬 Why GBA1 Matters in Parkinson’s Disease Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson’s. They are linked to earlier onset and more severe symptoms. These mutations reduce the function of an important enzyme called glucocerebrosidase (GCase), leading to the buildup of harmful proteins like α-synuclein and damage to brain cells. 💡 How SPR301 Works SPR301 uses a gene delivery system (AAV9 capsid) to transport a specially designed version of GCase—called GCase85—into the brain. GCase85 is more stable than the natural version of the enzyme and aims to reduce the toxic buildup that harms brain cells in GBA1-related Parkinson’s. 🧪 Key Preclinical Findings In laboratory studies, SPR301 showed: Significant reduction in α-synuclein buildup in nerve cells, a key marker of Parkinson’s disease. Greater effectiveness than earlier gene therapy approaches in models of GBA1 Parkinson’s. Broad brain distribution in non-human primates when delivered directly to both brain hemispheres. These early results suggest that SPR301 may be a best-in-class gene therapy for this form of Parkinson’s, which currently has no disease-modifying treatments. 🧱 What’s Next? Spur is continuing preclinical testing of SPR301 and plans to move it into Phase 1/2 clinical trials, which would involve human participants, in the future. 🧬 About Spur Therapeutics Spur Therapeutics is developing advanced gene therapies for chronic diseases, including Parkinson’s, Gaucher disease, and other serious conditions. Their mission is to improve lives through carefully engineered genetic treatments. If successful, SPR301 could become a transformational option for people with GBA1 Parkinson’s—a group that has long needed more effective therapies.